201 BROOKLINE AVENUE, BOSTON, MA
Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Sales Agreement with Leerink Partners for $100M Common Stock Offering
Amended material disclosure
Dr. Barbara Weber Resigns as Executive Chair of Tango Therapeutics
Appoints Robert Azelby to Board of Directors
Tango Therapeutics Enters Underwriting Agreement for $30.00 Offering
Investor Presentation
2026 Annual Meeting of Stockholders Held for Tango Therapeutics, Inc.
Q2
Q1
FY 2025
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
S-3ASR
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus